Document is current
Any future updates will be listed below
-
Authors
Philipp‐Abbrederis, Kathrin
Herrmann, Ken
Knop, Stefan
Schottelius, Margret
Eiber, Matthias
Lückerath, Katharina
Pietschmann, Elke
Habringer, Stefan
Gerngroß, Carlos
Franke, Katharina
Rudelius, Martina
Schirbel, Andreas
Lapa, Constantin
Schwamborn, Kristina
Steidle, Sabine
Hartmann, Elena
Rosenwald, Andreas
Kropf, Saskia
Beer, Ambros J
Peschel, Christian
Einsele, Hermann
Buck, Andreas K
Schwaiger, Markus
Götze, Katharina
Wester, Hans‐Jürgen
Keller, Ulrich
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB824)
Deutsche Forschungsgemeinschaft (KE 222/7‐1)
Deutsche Krebshilfe (111305)
German Cancer Consortium
- License Information
-
More Information
Article History
Received: 1 October 2014
Revised: 26 January 2015
Accepted: 26 January 2015
First Online: 3 March 2015
Conflict of interest
: HJ Wester and S Kropf are CEOs of Scintomics, the distributor of Pentixafor. The remaining authors declare that they have no conflict of interest.
